ATR 01
Alternative Names: ATR-01Latest Information Update: 29 May 2024
At a glance
- Originator Azitra
- Class Peptides; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Bacteria replacements; Filaggrin protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ichthyosis
Most Recent Events
- 29 May 2024 Azitra intends to file IND application for ATR 01 in Ichthyosis in the second half of 2025
- 16 Jan 2024 Azitra has patent protection for Methods and compositions for treating skin disease with recombinant microorganisms in USA
- 21 Feb 2023 Azitra has patents pending for engineering segment of human filaggrin protein